| Heading: |
Respiratory Syncytial Virus: Vaccination |
| Question ID: |
1795950 |
| UIN: |
HL6741 |
| House: |
Lords |
| Date tabled: |
2025-04-22 |
| Asking Member ID: |
4130 |
| Asking Member display name: |
Baroness Ritchie of Downpatrick
|
| Asking Member handle: |
MRitchieSD
|
| Asking Member Twitter reference: |
@MRitchieSD
|
| Member interest: |
false |
| Question text: |
To ask His Majesty's Government what assessment they have made of the impact of the UK’s vaccination programme for infant respiratory syncytial virus relative to other comparable countries with differing approaches such as the Republic of Ireland, Spain a |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-04-30 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
347 |
| Answering Member display name: |
Baroness Merron
|
| Answering Member handle: |
|
| Answering Member Twitter reference: |
Baroness Merron
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The United Kingdom’s maternal immunisation programme to protect infants started in September 2024 and is based on advice from the Joint Committee on Vaccination and Immunisation (JCVI). The JCVI last met in February 2025 and noted promising data shared co... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |